ReviewCurrent opinion in nephrology and hypertension2020
The nephrologist's guide to cannabis and cannabinoids.
Review in Current opinion in nephrology and hypertension, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 49 citations in OpenAlex.
- Weighted analysis of the association between cannabis smoking and chronic pain intensity among hemodialysis patients.Scientific reports · 2026Observational
- The interplay of maturity-onset diabetes of the young, obesity, uncontrolled hypertension, and cannabinoid hyperemesis in the progression to end-stage renal disease: a case report.Frontiers in medicine · 2026Article
- The Present and Future of Pain Management in Patients With Chronic Kidney Disease: A Narrative Review.Cureus · 2025Review
- The Action of Cannabidiol on Doxycycline Cytotoxicity in Human Cells-In Vitro Study.Molecules (Basel, Switzerland) · 2025Article
- Pharmacokinetics and Side Effects of ΔKidney international reports · 2025Article
- Review
- Protective Action of Cannabidiol on Tiamulin Toxicity in Humans-In Vitro Study.International journal of molecular sciences · 2024Article
- The effects of cannabinoids on the kidney.Acta physiologica (Oxford, England) · 2024Review
- Cannabinoid receptor type 1 activation causes a water diuresis by inducing an acute central diabetes insipidus in mice.American journal of physiology. Renal physiology · 2024Article
- A Retrospective Cohort Study That Examined the Impact of Cannabis Consumption on Long-Term Kidney Outcomes.Cannabis and cannabinoid research · 2024Article
- The intervention of cannabinoid receptor in chronic and acute kidney disease animal models: a systematic review and meta-analysis.Diabetology & metabolic syndrome · 2024Review
- Cannabis Use, Perspectives, and Experiences Among Patients Receiving Hemodialysis: A Descriptive Patient Survey.Canadian journal of kidney health and disease · 2024Article
- Trends in past-month cannabis use among US adults across a range of disabilities and health conditions, 2015-2019.Preventive medicine · 2023Article
- A Case of a Patient With Cannabis Hyperemesis Syndrome Along With Recurrent Nephrolithiasis.Cureus · 2023Article
- Medical cannabis for pain management in patients undergoing chronic hemodialysis: randomized, double-blind, cross-over, feasibility study.Clinical kidney journal · 2023Article
- Cannabis Use and CKD: Epidemiological Associations and Mendelian Randomization.Kidney medicine · 2023Article
- Renal Papillary Necrosis (RPN) in an African Population: Disease Patterns, Relevant Pathways, and Management.Biomedicines · 2022Review
- Self-reported marijuana use and its effects on overall approval in potential living kidney donors.Clinical transplantation · 2022Article
- Lessons for the clinical nephrologist: unexplained tacrolimus overdose in a kidney transplant patient.Journal of nephrology · 2022Article
- Medical cannabis for the treatment of comorbid symptoms in children with autism spectrum disorder: An interim analysis of biochemical safety.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
purpose of reviewCannabis (marijuana, weed, pot, ganja, Mary Jane) is the most commonly used federally illicit drug in the United States. The present review provides an overview of cannabis and cannabinoids with relevance to the practice of nephrology so that clinicians can best take care of patients. RECENT
findingsCannabis may have medicinal benefits for treating symptoms of advanced chronic kidney disease (CKD) and end-stage renal disease including as a pain adjuvant potentially reducing the need for opioids. Cannabis does not seem to affect kidney function in healthy individuals. However, renal function should be closely monitored in those with CKD, the lowest effective dose should be used, and smoking should be avoided. Cannabis use may delay transplant candidate listing or contribute to ineligibility. Cannabidiol (CBD) has recently exploded in popularity. Although generally well tolerated, safe without significant side effects, and effective for a variety of neurological and psychiatric conditions, consumers have easy access to a wide range of unregulated CBD products, some with inaccurate labeling and false health claims. Importantly, CBD may raise tacrolimus levels. SUMMARY: Patients and healthcare professionals have little guidance or evidence regarding the impact of cannabis use on people with kidney disease. This knowledge gap will remain as long as federal regulations remain prohibitively restrictive towards prospective research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.